Addex Therapeutics (ADXN) Operating Income (2018 - 2025)

Addex Therapeutics has disclosed Operating Income across 8 years of filings, most recently posting -$974990.3 for Q4 2025.

• Operating Income for Q4 2025 came in at -$974990.3, up 69.0% year-over-year; the trailing twelve-month figure through Dec 2025 was -$3.4 million (up 40.89% YoY), and the FY2025 annual result was -$3.4 million, down 7.94% from the prior year.
• Operating Income came in at -$974990.3 for Q4 2025 at Addex Therapeutics, down from -$870295.0 in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$397495.9 in Q1 2023 to a low of -$21.3 million in Q4 2022.
• The 5-year median for Operating Income is -$1.8 million (2023), against an average of -$4.1 million.
• Across the five-year window, Operating Income jumped 94.02% in 2023 and sank 127.15% in 2024, its largest moves.
• Addex Therapeutics' Operating Income stood at -$16.8 million in 2021, then retreated by 26.66% to -$21.3 million in 2022, then surged by 88.13% to -$2.5 million in 2023, then decreased by 24.37% to -$3.1 million in 2024, then soared by 69.0% to -$974990.3 in 2025.
• The last three Operating Income figures came in at -$974990.3 (Q4 2025), -$870295.0 (Q3 2025), and -$885260.3 (Q2 2025), per Business Quant data.